Chapter 5 NERVE AGENTS

Total Page:16

File Type:pdf, Size:1020Kb

Chapter 5 NERVE AGENTS Nerve Agents Chapter 5 NERVE AGENTS FREDERICK R. SIDELL, M.D.* INTRODUCTION HISTORY PHARMACOLOGY OF CHOLINESTERASE INHIBITORS Cholinesterase in Tissue Blood Cholinesterases Nerve Agents EXPOSURE ROUTES Inhalational Exposure to Vapor Dermal Exposure to Liquid EFFECTS ON ORGANS AND ORGAN SYSTEMS The Eye The Nose Pulmonary System Skeletal Musculature Central Nervous System and Behavior Cardiovascular System GENERAL TREATMENT PRINCIPLES Terminating the Exposure Ventilatory Support Atropine Therapy Oxime Therapy Anticonvulsive Therapy Therapy for Cardiac Arrhythmias SPECIFIC TREATMENT BY EXPOSURE CATEGORY Suspected Exposure Minimal Exposure Mild Exposure Moderate Exposure Moderately Severe Exposure Severe Exposure RETURN TO DUTY SUMMARY *Formerly, Chief, Chemical Casualty Care Office, and Director, Medical Management of Chemical Casualties Course, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland 21010-5425; currently, Chemical Casualty Consultant, 14 Brooks Road, Bel Air, Maryland 21014 129 Medical Aspects of Chemical and Biological Warfare INTRODUCTION Nerve agents are extremely toxic chemicals that The military stockpiles of several major powers were first developed in secrecy before and during are known to include nerve agents, and the arma- World War II primarily for military use. Related mentaria of other countries are thought to contain substances are used in medicine, in pharmacology, them as well (see Chapter 4, The Chemical War- and for other purposes, such as insecticides, but fare Threat and the Military Healthcare Provider). they lack the potency of the military agents. Much Because of the possibility of nerve agent use in of the basic knowledge about the clinical effects of future conflicts, military medical personnel should nerve agents comes from research performed in the have some knowledge of these agents, their effects, decades immediately following World War II. and the proper therapy for treating casualties. HISTORY Possibly the earliest recorded use of a substance in Germany; the “V” allegedly stands for venom- that works, like nerve agents, by inhibiting cho- ous. GF is an old agent, previously discarded by linesterase (ChE) is by native tribesmen of western the United States as being of no interest. During the Africa who used the Calabar bean as an “ordeal Persian Gulf War, it was believed that Iraq might poison” in witchcraft trials.1,2 An extract, “the elixir have GF in its arsenal; however, interest has waned of the Calabar bean,” was later used medicinally, 3 again and GF has retreated to obscurity. and in 1864, the active principle was isolated by Lange and Krueger reported on the marked po- Jobst and Hesse and called physostigmine.1 Vee and tency of organophosphorus compounds in 1932 af- Leven independently isolated this same substance ter noting the effects of the vapors of dimethyl and in 1865 and named it eserine,1 hence its dual nomen- diethyl phosphorofluoridate on themselves.1,4 clature. Shortly thereafter, the German company I. G. The first organophosphorus ChE inhibitor was Farbenindustrie developed an interest in organo- probably tetraethyl pyrophosphate (TEPP), synthe- phosphorus compounds as insecticides. On 23 De- sized by Wurtz and tasted (with no ill results) by cember 1936, Gerhard Schrader, who headed the Clermont in 1854.4 During the next 80 years, chem- company’s research effort, synthesized what today ists (such as Michaelis, Arbusow, and Nylen) made is known as tabun.5,6 Like Lange and Krueger, he numerous advances in organophosphorus chemis- noted the toxicity (miosis and discomfort) of the try, but generally they did not realize the toxicity vapors of the substance in himself. of the substances with which they were working.4 Over a year later, Schrader synthesized a second In the early 1930s, interest in both physostigmine- organophosphorus compound and named it sarin type (reversible) and organophosphorus-type (irre- in honor of those who were instrumental in its de- versible) ChE inhibitors increased. (The terms “re- velopment and production: Schrader, Ambros, versible” and “irreversible” refer to the duration of Rudriger, and van der Linde.5 Because the German binding of the compound with the enzyme ChE; see Ministry of Defense required that substances pass- the Mechanism of Action section below.) The revers- ing certain toxicity tests be submitted to the gov- ible type, most of which are carbamates, were de- ernment for further investigation, these compounds veloped for treating conditions such as intestinal were examined for possible military use. atony, myasthenia gravis, and glaucoma; for ex- The potential of tabun and sarin as weapons ample, treating gastric atony with neostigmine was was soon realized. A large production facility was described in 1931.1 built in Dyhernfurth and production of tabun was Five organophosphorus compounds are gener- begun in 1942.5,6 Sarin was also produced in ally regarded as nerve agents. They are commonly Dyhernfurth and possibly at another plant in known as tabun (North Atlantic Treaty Organiza- Falkenhagen.6 Late in World War II, Soviet troops tion [NATO] military designation, GA), sarin (GB), captured the Dyhernfurth facility (then in Germany, and soman (GD); and GF and VX (also NATO mili- now in Poland), dismantled it, and moved it, along tary designations; these compounds have no com- with key personnel, to the former Soviet Union, mon names). The agents in the “G” series allegedly where production of the agents commenced in were given the code letter G because they originated 1946.6 130 Nerve Agents About 10,000 to 30,000 tons of tabun and smaller example, GF, which may have been first synthesized quantities of sarin were produced and put into about 1949 by a chemist in another country in the munitions by the Germans during World War II, but search for other nerve agents, was studied in both these weapons were never used.6 Why they were the United States and the United Kingdom. It was not remains a matter of conjecture. then discarded for reasons that are not entirely clear. In the waning days of World War II, troops of Possible explanations are that it was too expensive the United States and the United Kingdom captured to manufacture or that there was no perceived need some of these munitions, which were being stored for an agent with its properties. The manufactur- at Raubkammer, a German testing facility. The mu- ing process for GF is apparently similar to that for nitions, which contained an agent unknown to sci- GB. During the Persian Gulf War (1990–1991), Iraq entists in the United Kingdom and the United was believed to have switched from the manufac- States, were taken to the two countries for exami- ture of GB to the manufacture of GF when the pre- nation. Over a single weekend, a small group of cursors of GB, but not those of GF, were embargoed. scientists at the U.K. Chemical Defence Establish- The United States began to produce sarin in the ment, working despite miosis caused by accidental early 1950s, and VX in the early 1960s, for potential exposure to the agent vapor, elucidated the phar- military use; production continued for about a de- macology and toxicity of tabun and documented the cade.6 The U.S. munitions inventory today contains antidotal activity of atropine.7 these two nerve agents in 30- to 45-year-old M55 Thus, during the latter part of World War II, Ger- rockets; land mines; 105-mm, 155-mm, and 8-in. many possessed chemical weapons against which projectiles; 500-lb and 750-lb bombs; wet-eye bombs its foes had little protection and no antidotes. (one of a family of “eye” bombs, which has liquid Use of these weapons probably would have been chemical [wet] contents); spray tanks; and bulk con- devastating and might have altered the outcome of tainers.9 These munitions are stored at six depots that conflict. The Germans had tested nerve agents within the continental United States (CONUS) and on inmates of concentration camps, not only to in- one outside the continent; the locations of these vestigate their intoxicating effects but also to de- depots are public knowledge.10 The six CONUS velop antidotes.8 Many casualties, including some depots are near Tooelle, Utah; Umatilla, Oregon; fatalities, were reported among the plant work- Anniston, Alabama; Pine Bluff, Arkansas; Newport, ers at Dyhernfurth; the medical staff there eventu- Indiana; and Richmond, Kentucky; the seventh de- ally developed antidotal compounds.5 The Allies pot is on Johnston Island in the Pacific Ocean. were unaware of these German experiments until Sarin has also been used in terrorist attacks. In the close of the war, months after the initial U.K. June 1994, members of a Japanese cult released sarin studies.7 in an apartment complex in Matsumoto, Japan. Al- Soman was synthesized in 1944 by Richard Kuhn though there were almost 300 casualties, including of Germany, again in a search for insecticides. 6 Small 7 dead, this event was not well publicized. On 20 amounts were produced, but development had not March 1995, sarin was released on Tokyo subways. proceeded far by the end of the war. The nerve agent More than 5,500 people sought medical care; about VX was first synthesized by an industrial concern 4,000 had no effects from the agent but 12 casual- in the United Kingdom in the early 1950s6 and was ties died. This incident required a major expendi- given to the United States for military development. ture of medical resources to triage and care for the Other potential nerve agents were synthesized casualties. (Also see Chapter 1, Overview: Defense by scientists in the United States and United King- Against the Effects of Chemical and Biological War- dom but were not developed for military use. For fare Agents). PHARMACOLOGY OF CHOLINESTERASE INHIBITORS Cholinesterase in Tissue nism and, in a broad sense, can also be considered nerve agents.
Recommended publications
  • Development and Validation of a Method for the Simultaneous
    CORE Metadata, citation and similar papers at core.ac.uk Provided by UGD Academic Repository American Journal of Applie d Chemistry 2014; 2(4): 46-54 Published online August 10, 2014 (http://www.sciencepublishinggroup.com/j/ajac) doi: 10.11648/j.ajac.20140204.11 ISSN: 2330-8753 (Print); ISSN: 2330-8745 (Online) Development and validation of a method for the simultaneous determination of 20 organophosphorus pesticide residues in corn by accelerated solvent extraction and gas chromatography with nitrogen phosphorus detection Vesna Kostik *, Biljana Gjorgeska, Bistra Angelovska Medical Faculty, Department of Pharmacy, University “Goce Delchev”, Shtip, Republic of Macedonia Email address: [email protected] (V. Kostik), [email protected] (B. Gjorgeska), [email protected] (B. Angelovska) To cite this article: Vesna Kostik, Biljana Gjorgeska, Bistra Angelovska. Development and Validation of a Method for the Simultaneous Determination of 20 Organophosphorus Pesticide Residues in Corn by Accelerated Solvent Extraction and Gas Chromatography with Nitrogen Phosphorus Detection. American Journal of Applied Chemistry. Vol. 2, No. 4, 2014, pp. 46-54. doi: 10.11648/j.ajac.20140204.11 Abstract: The method for simultaneous determination of 20 organophosphorus pesticide residues in corn samples has been developed and validated. For the extraction of organophosporus pesticide residues from the samples, the accelerated solvent technique with the mixture of dichloromethane: acetone (1:1, V/V ) was used. Clean up was done using liquid – liquid extraction with n – hexane, followed by solid phase extraction on primary secondary amine adsorbent, and elution with the mixture of acetone: toluene (65:35). The determination of the pesticides was carried out by gas chromatography with nitrogen phosphorus detection.
    [Show full text]
  • Mechanism of Central Hypopnoea Induced by Organic Phosphorus
    www.nature.com/scientificreports OPEN Mechanism of central hypopnoea induced by organic phosphorus poisoning Kazuhito Nomura*, Eichi Narimatsu, Hiroyuki Inoue, Ryoko Kyan, Keigo Sawamoto, Shuji Uemura, Ryuichiro Kakizaki & Keisuke Harada Whether central apnoea or hypopnoea can be induced by organophosphorus poisoning remains unknown to date. By using the acute brainstem slice method and multi-electrode array system, we established a paraoxon (a typical acetylcholinesterase inhibitor) poisoning model to investigate the time-dependent changes in respiratory burst amplitudes of the pre-Bötzinger complex (respiratory rhythm generator). We then determined whether pralidoxime or atropine, which are antidotes of paraoxon, could counteract the efects of paraoxon. Herein, we showed that paraoxon signifcantly decreased the respiratory burst amplitude of the pre-Bötzinger complex (p < 0.05). Moreover, pralidoxime and atropine could suppress the decrease in amplitude by paraoxon (p < 0.05). Paraoxon directly impaired the pre-Bötzinger complex, and the fndings implied that this impairment caused central apnoea or hypopnoea. Pralidoxime and atropine could therapeutically attenuate the impairment. This study is the frst to prove the usefulness of the multi-electrode array method for electrophysiological and toxicological studies in the mammalian brainstem. Te pre-Bötzinger complex (preBötC) in the ventrolateral lower brainstem is essential for the formation of the unconscious breathing rhythm in mammals1,2. Tis is because the cyclic burst excitation generated from preBötC synchronizes with the respiratory rhythm through phrenic nerve fring and the diaphragmatic contractions, and destruction of preBötC causes the disappearance of the rhythm. Periodic respiratory burst excitation has also been confrmed from an island specimen derived by isolating preBötC in an island shape to block input from other neurons2.
    [Show full text]
  • Chemical Name Federal P Code CAS Registry Number Acutely
    Acutely / Extremely Hazardous Waste List Federal P CAS Registry Acutely / Extremely Chemical Name Code Number Hazardous 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- P059 76-44-8 Acutely Hazardous 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide P050 115-29-7 Acutely Hazardous Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- P197 17702-57-7 Acutely Hazardous 1-(o-Chlorophenyl)thiourea P026 5344-82-1 Acutely Hazardous 1-(o-Chlorophenyl)thiourea 5344-82-1 Extremely Hazardous 1,1,1-Trichloro-2, -bis(p-methoxyphenyl)ethane Extremely Hazardous 1,1a,2,2,3,3a,4,5,5,5a,5b,6-Dodecachlorooctahydro-1,3,4-metheno-1H-cyclobuta (cd) pentalene, Dechlorane Extremely Hazardous 1,1a,3,3a,4,5,5,5a,5b,6-Decachloro--octahydro-1,2,4-metheno-2H-cyclobuta (cd) pentalen-2- one, chlorecone Extremely Hazardous 1,1-Dimethylhydrazine 57-14-7 Extremely Hazardous 1,2,3,4,10,10-Hexachloro-6,7-epoxy-1,4,4,4a,5,6,7,8,8a-octahydro-1,4-endo-endo-5,8- dimethanonaph-thalene Extremely Hazardous 1,2,3-Propanetriol, trinitrate P081 55-63-0 Acutely Hazardous 1,2,3-Propanetriol, trinitrate 55-63-0 Extremely Hazardous 1,2,4,5,6,7,8,8-Octachloro-4,7-methano-3a,4,7,7a-tetra- hydro- indane Extremely Hazardous 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 51-43-4 Extremely Hazardous 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, P042 51-43-4 Acutely Hazardous 1,2-Dibromo-3-chloropropane 96-12-8 Extremely Hazardous 1,2-Propylenimine P067 75-55-8 Acutely Hazardous 1,2-Propylenimine 75-55-8 Extremely Hazardous 1,3,4,5,6,7,8,8-Octachloro-1,3,3a,4,7,7a-hexahydro-4,7-methanoisobenzofuran Extremely Hazardous 1,3-Dithiolane-2-carboxaldehyde, 2,4-dimethyl-, O- [(methylamino)-carbonyl]oxime 26419-73-8 Extremely Hazardous 1,3-Dithiolane-2-carboxaldehyde, 2,4-dimethyl-, O- [(methylamino)-carbonyl]oxime.
    [Show full text]
  • Medical Control of the Glaucomas
    Br J Ophthalmol: first published as 10.1136/bjo.56.3.272 on 1 March 1972. Downloaded from 272 call these cases of malignant glaucoma, using the old term in a new broader sense, or whether we devise a new terminology to describe such phenomena should perhaps await further experimentation. Conclusion Many questions still remain in regard to malignant glaucoma, and it is to be hoped that future observations will gradually elucidate them. Today, however, medical therapy consisting of the concurrent use of mydriatic-cycloplegic drops, carbonic anhydrase inhibitors, and hyperosmotic agents is available, and is proving to be effective in half the cases when continued for 5 days. In addition, the vitreous surgery described above is in our opinion a safe and reliable surgical procedure in cases of malignant glaucoma which are not relieved by medical therapy. COMMENTARY MALIGNANT GLAUCOMA Chandler's anterior chamber deepening procedure with gonioscopy used for diagnosis of the extent of synaechial closure of the angle does not seem to predispose to malignant glaucoma. Even though it is known that there is a predisposition to malignant glaucoma in the fellow eye, this eye should always be treated with a peripheral iridectomy as early as possible after the onset of malignant glaucoma in the opposite eye. No medical treatment of any sort should be given before the peripheral iridectomy, since both miotics and mydriatics may be dangerous before surgerycopyright. is performed. If the fellow eye has been operated upon when the angle has been completely open, then malignant glaucoma has not occurred. However, if angle-closure is present in the fellow eye at the time of surgery, then malignant glaucoma becomes very common.
    [Show full text]
  • Malathion Human Health and Ecological Risk Assessment Final Report
    SERA TR-052-02-02c Malathion Human Health and Ecological Risk Assessment Final Report Submitted to: Paul Mistretta, COR USDA/Forest Service, Southern Region 1720 Peachtree RD, NW Atlanta, Georgia 30309 USDA Forest Service Contract: AG-3187-C-06-0010 USDA Forest Order Number: AG-43ZP-D-06-0012 SERA Internal Task No. 52-02 Submitted by: Patrick R. Durkin Syracuse Environmental Research Associates, Inc. 5100 Highbridge St., 42C Fayetteville, New York 13066-0950 Fax: (315) 637-0445 E-Mail: [email protected] Home Page: www.sera-inc.com May 12, 2008 Table of Contents Table of Contents............................................................................................................................ ii List of Figures................................................................................................................................. v List of Tables ................................................................................................................................. vi List of Appendices ......................................................................................................................... vi List of Attachments........................................................................................................................ vi ACRONYMS, ABBREVIATIONS, AND SYMBOLS ............................................................... vii COMMON UNIT CONVERSIONS AND ABBREVIATIONS.................................................... x CONVERSION OF SCIENTIFIC NOTATION ..........................................................................
    [Show full text]
  • Table II. EPCRA Section 313 Chemical List for Reporting Year 2017 (Including Toxic Chemical Categories)
    Table II. EPCRA Section 313 Chemical List For Reporting Year 2017 (including Toxic Chemical Categories) Individually listed EPCRA Section 313 chemicals with CAS numbers are arranged alphabetically starting on page II-3. Following the alphabetical list, the EPCRA Section 313 chemicals are arranged in CAS number order. Covered chemical categories follow. Note: Chemicals may be added to or deleted from the list. The Emergency Planning and Community Right-to-Know Call Center or the TRI-Listed Chemicals website will provide up-to-date information on the status of these changes. See section B.3.c of the instructions for more information on the de minimis % limits listed below. There are no de minimis levels for PBT chemicals since the de minimis exemption is not available for these chemicals (an asterisk appears where a de minimis limit would otherwise appear in Table II). However, for purposes of the supplier notification requirement only, such limits are provided in Appendix C. Chemical Qualifiers Certain EPCRA Section 313 chemicals listed in Table II have parenthetic “qualifiers.” These qualifiers indicate that these EPCRA Section 313 chemicals are subject to the section 313 reporting requirements if manufactured, processed, or otherwise used in a specific form or when a certain activity is performed. An EPCRA Section 313 chemical that is listed without a qualifier is subject to reporting in all forms in which it is manufactured, processed, and otherwise used. The following chemicals are reportable only if they are manufactured, processed, or otherwise used in the specific form(s) listed below: Chemical/ Chemical Category CAS Number Qualifier Aluminum (fume or dust) 7429-90-5 Only if it is a fume or dust form.
    [Show full text]
  • Amending Annex II to Directives 76/895/EEC and 86/362/EEC
    20 . 5 . 88 Official Journal of the European Communities No L 126/53 COUNCIL DIRECTIVE of 16 May 1988 amending Annex II to Directives 76/895/EEC and 86/362/EEC relating to the fixing of maximum levels for pesticide residues in and on fruit and vegetables and cereals respectively (88/298/EEC) THE COUNCIL OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Economic Community, Having regard to Council Directive 76/895/EEC of 23 November 1976 relating to the fixing of maximum levels for pesticide residues in and on fruit and vegetables 0), as last amended by Regulation (EEC) No 3768/85 (2), and in particular Article 5 thereof, Having regard to Council Directive 86/362/EEC of 24 July 1986 on the fixing of maximum levels for pesticide residues in and on cereals (3), and in particular Article 1 1 thereof, Having regard to the proposal from the Commission, Whereas, in the light of technical and scientific progress and of the requirements of public health and agriculture, it is necessary to amend the provisions, particularly the maximum levels, contained in Annex II to Directive 76/895/EEC relating to captafol, captan, chlorfenvinphos, dodine, fenitrothion, folpet, formothion and malathion ; Whereas, for the same reasons, it seems desirable to update Directive 76/895/EEC by adding provisions relating to further pesticides, residues of which may occur in and on fruit and vegetables, namely, ethion, ethylene dibromide, mevinphos, phosalone and 2, 4, 5-T, arid to update Directive 86/362/EEC by adding provisions relating to a further pesticide the residues of which may occur in cereals, namely, captafol, HAS ADOPTED THIS DIRECTIVE : Article 1 Annex II to Directive 76/895/EEC is hereby amended as follows : 1 .
    [Show full text]
  • Demecarium Bromide/Homatropine 1881
    Demecarium Bromide/Homatropine 1881 Dyflos (BAN) junctival injection of pralidoxime has been used to reverse severe ocular adverse effects. Supportive treatment, including assisted DFP; Difluorophate; Di-isopropyl Fluorophosphate; Di-isopro- ventilation, should be given as necessary. CH3 pylfluorophosphonate; Fluostigmine; Isoflurofato; Isoflurophate. Di-isopropyl phosphorofluoridate. To prevent or reduce development of iris cysts in patients receiv- N ing ecothiopate eye drops, phenylephrine eye drops may be giv- C6H14FO3P = 184.1. en simultaneously. CAS — 55-91-4. ATC — S01EB07. Precautions ATC Vet — QS01EB07. As for Neostigmine, p.632. For precautions of miotics, see also OH under Pilocarpine, p.1885. In general, as with other long-acting anticholinesterases, ecothiopate should be used only where ther- O apy with other drugs has proved ineffective. Ecothiopate iodide CH3 should not be used in patients with iodine hypersensitivity. O O H3C O Interactions P CH3 As for Neostigmine, p.632. The possibility of an interaction re- O F mains for a considerable time after stopping long-acting anti- Homatropine Hydrobromide (BANM) CH3 cholinesterases such as ecothiopate. Homatr. Hydrobrom.; Homatropiinihydrobromidi; Homatropi- Pharmacopoeias. In US. Uses and Administration na, hidrobromuro de; Homatropine, bromhydrate d’; Homatro- USP 31 (Isoflurophate). A clear, colourless, or faintly yellow liq- Ecothiopate is an irreversible inhibitor of cholinesterase; its ac- pin-hidrobromid; Homatropinhydrobromid; Homatropin-hydro- uid. Specific gravity about 1.05. Sparingly soluble in water; sol- tions are similar to those of neostigmine (p.632) but much more bromid; Homatropini hydrobromidum; Homatropinium Bro- uble in alcohol and in vegetable oils. It is decomposed by mois- prolonged. Its miotic action begins within 1 hour of its applica- mide; Homatropino hidrobromidas; Homatropinum Bromatum; ture with the evolution of hydrogen fluoride.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • Healthcare Resource
    Health Care Resource: Links between Pesticide Exposures and Mental Health Prepared by the Mental Health and Environment Working Group of the Collaborative on Health and the Environment www.healthandenvironment.org Mental Health Effects from Pesticide Exposure Exposure to pesticides can have behavioral and psychiatric consequences. The purpose of this resource is to help mental health clinicians and health care providers become aware of the association between pesticide exposure and these consequences and to provide links to relevant research findings. Many people are at risk of pesticide exposure, including those who: • work in agriculture, landscaping or other settings (such as grocery stores, schools, daycares and office buildings) in which pest problems are treated with chemicals; • live downwind from where aerial spraying of pesticides is done; • live in communities where spray and runoff can contaminate both surface and ground water; or • live in urban dwellings where pest control is used. Outside use may take months for the pesticide to degrade to half-life or roughly half potency. Indoors there are no degrading elements such as sunshine, soil or rain to degrade potency; these undegraded pesticides can be re-suspended into the air in dust particles. Health care providers should consider the possibility that the symptoms associated with mental health disorders, such as irritability, depression or anxiety, may be the result of acute or chronic pesticide exposure. No matter what the presenting ailment may be, clinicians who care for individuals either at risk of pesticide exposure or those with known exposure are encouraged to inquire about the presence of depression, anxiety, or any of the other symptoms listed below.
    [Show full text]
  • Galantamine 4Mg/Ml Oral Solution Package Leaflet
    Package leaflet: Information for the user Galantamine 4mg/ml Oral Solution Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. n Keep this leaflet. You may need to read it again. n If you have any further questions, ask your doctor or pharmacist. n This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. n If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Galantamine Oral Solution is and what it is used for 2. What you need to know before you take Galantamine Oral Solution 3. How to take Galantamine Oral Solution 4. Possible side effects 5. How to store Galantamine Oral Solution 6. Contents of the pack and other information 1. What Galantamine Oral Solution is and what it is used for What your medicine is The full name of your medicine is Galantamine 4mg/ml Oral Solution. In this leaflet the shorter name Galantamine is used. Galantamine belongs to a group of medicines known as ‘anti-dementia’ medicines. What your medicine is used for Galantamine is used in adults to treat the symptoms of mild to moderately severe Alzheimer’s disease. This is a type of dementia that alters the way the brain works. Alzheimer’s disease causes memory loss, confusion and changes in behaviour, which make it increasingly difficult to carry out normal daily tasks.
    [Show full text]
  • Environmental Health Criteria 63 ORGANOPHOSPHORUS
    Environmental Health Criteria 63 ORGANOPHOSPHORUS INSECTICIDES: A GENERAL INTRODUCTION Please note that the layout and pagination of this web version are not identical with the printed version. Organophophorus insecticides: a general introduction (EHC 63, 1986) INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY ENVIRONMENTAL HEALTH CRITERIA 63 ORGANOPHOSPHORUS INSECTICIDES: A GENERAL INTRODUCTION This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organisation, or the World Health Organization. Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization World Health Orgnization Geneva, 1986 The International Programme on Chemical Safety (IPCS) is a joint venture of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization. The main objective of the IPCS is to carry out and disseminate evaluations of the effects of chemicals on human health and the quality of the environment. Supporting activities include the development of epidemiological, experimental laboratory, and risk-assessment methods that could produce internationally comparable results, and the development of manpower in the field of toxicology. Other activities carried out by the IPCS include the development of know-how for coping with chemical accidents, coordination
    [Show full text]